Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Carisma Therapeutics Inc.SESN · Entity 74418 | General Counsel & Secretary | March 02, 2023 | March 06, 2023 |
| Definium Therapeutics, Inc.DFTX · Entity 3884 | Chief Legal Officer | September 14, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Carisma Therapeutics Inc.
Report date March 02, 2023 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 378,651 |
Ending reported balance
After 2023-03-02 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2023-03-02 · Sale · Disposed 100,978 · Balance 198,716 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above. Row 2 · 2023-03-02 · Exercise / conversion · Acquired 185,000 · Balance 383,716 F3: Represents performance-based restricted stock units granted on October 1, 2021, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc. Row 3 · 2023-03-02 · Sale · Disposed 73,361 · Balance 310,355 F4: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on October 21, 2021. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above. Row 4 · 2023-03-02 · Exercise / conversion · Acquired 113,175 · Balance 423,530 F5: Represents performance-based restricted stock units granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc. Row 5 · 2023-03-02 · Sale · Disposed 44,879 · Balance 378,651 F6: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above.
F3: Represents performance-based restricted stock units granted on October 1, 2021, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc.
F4: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on October 21, 2021. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F5: Represents performance-based restricted stock units granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc.
F6: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Definium Therapeutics, Inc.
Report date September 14, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 508,279 |
Reported balance
After 2026-09-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-14 · Grant · Acquired 125,000 · Balance 508,279 F1: The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. F2: Amount includes 208 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.
F2: Amount includes 208 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 14, 2026 12:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-389889 · ownership.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 508,279 F1 · shares: The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. F2 · balance_after: Amount includes 208 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026. Read SEC document |
| August 12, 2026 Filed Aug 12, 2026 12:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-345837 · ownership.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,071 F1 · shares: The common shares represent the second tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:30 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | SaleCommon Shares | 13,008 | $45.03 | $585,750.24 |
DisclosureSEC source: 0001193125-26-285567 · ownership.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 320,571 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024. Read SEC document |
| June 22, 2026 Filed Jun 22, 2026 13:45 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-276879 · ownership.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,579 F1 · shares: The common shares represent the first tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. Read SEC document |
| March 25, 2026 Filed Mar 26, 2026 22:42 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | SaleCommon Shares | 10,702 | $18.47 | $197,665.94 |
DisclosureSEC source: 0001193125-26-126827 · ownership.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,079 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2026 at prices ranging from $18.36 to $18.80. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Amount includes 793 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:55 UTC | Definium Therapeutics, Inc. DFTX · Entity 3884 | GrantCommon Shares | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-039579 · ownership.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407,576 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 22:00 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 11,276 | $13.15 | $148,244.44 |
DisclosureSEC source: 0001193125-25-335481 · ownership.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 282,576 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2025 at prices ranging from $13.02 to $13.33. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2025 Filed Sep 26, 2025 21:35 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 11,278 | $9.77 | $110,186.06 |
DisclosureSEC source: 0001193125-25-220848 · ownership.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 293,852 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024. Read SEC document |
| June 25, 2025 Filed Jun 26, 2025 20:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 11,491 | $6.80 | $78,138.80 |
DisclosureSEC source: 0000950170-25-090431 · ownership.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 305,130 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2025 at prices ranging from $6.67 to $7.03. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 25, 2025 Filed Mar 26, 2025 21:00 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 6,576 | $6.74 | $44,322.24 |
DisclosureSEC source: 0000950170-25-045394 · ownership.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,621 F1 · shares: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2025 at prices ranging from $6.67 to $6.79. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 20:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantCommon Shares | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-038798 · ownership.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,197 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| December 26, 2024 Filed Dec 27, 2024 21:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 4,519 | $7.43 | $33,576.17 |
DisclosureSEC source: 0001104659-24-132160 · tm2432133-1_4seq1.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,197 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2024 at prices ranging from $6.98 to $7.66. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2024 Filed Sep 26, 2024 00:28 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 4,430 | $5.98 | $26,491.40 |
DisclosureSEC source: 0000950170-24-109447 · ownership.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,716 F1 · kind: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2024 at prices ranging from $5.95 to $6.07. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 25, 2024 Filed Jun 25, 2024 23:00 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | SaleCommon Shares | 17,854 | $7.22 | $128,905.88 |
DisclosureSEC source: 0000950170-24-077497 · ownership.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,146 F1 · shares: Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024. F2 · price: The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2024 at prices ranging from $7.20 to $7.26. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:45 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0000950170-24-023201 · ownership.xml · derivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2034-02-26 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in 48 equal monthly installments, with the first installment vesting on March 27, 2024, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 20:45 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantCommon Shares | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024335 · doc4.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer, with 25% of the RSUs vesting on April 13, 2024, and the remaining RSUs vesting in 12 equal quarterly installments over the subsequent three years thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 20:46 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | SaleCommon Stock | 44,879 | $0.59 | $26,343.97 |
DisclosureSEC source: 0001485003-23-000111 · wf-form4_167815358414793.xml · nonDerivative · entry 5 Sullivan Mark · CIK 0001331843 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,651 F6 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 20:46 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | Exercise / conversionCommon Stock | 113,175 | $0.59 | $66,433.73 |
DisclosureSEC source: 0001485003-23-000111 · wf-form4_167815358414793.xml · nonDerivative · entry 4 Sullivan Mark · CIK 0001331843 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Represents performance-based restricted stock units granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 20:46 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | SaleCommon Stock | 73,361 | $0.59 | $43,062.91 |
DisclosureSEC source: 0001485003-23-000111 · wf-form4_167815358414793.xml · nonDerivative · entry 3 Sullivan Mark · CIK 0001331843 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,355 F4 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on October 21, 2021. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 20:46 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | Exercise / conversionCommon Stock | 185,000 | $0.59 | $108,595.00 |
DisclosureSEC source: 0001485003-23-000111 · wf-form4_167815358414793.xml · nonDerivative · entry 2 Sullivan Mark · CIK 0001331843 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents performance-based restricted stock units granted on October 1, 2021, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 20:46 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | SaleCommon Stock | 100,978 | $0.59 | $59,274.09 |
DisclosureSEC source: 0001485003-23-000111 · wf-form4_167815358414793.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,716 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 19:38 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | SaleCommon Stock | 39,831 | $0.59 | $23,392.75 |
DisclosureSEC source: 0001485003-23-000066 · wf-form4_167719907774834.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,694 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the price set forth above. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 20:37 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantCommon Stock | 339,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001485003-22-000022 · wf-form4_164566664903724.xml · nonDerivative · entry 1 Sullivan Mark · CIK 0001331843 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,525 F1 · shares: Represents restricted stock units ("RSUs") which shall vest annually in equal amounts over a four-year period following the grant date, so long as the reporting person remains employed by Sesen Bio, Inc. (the "Company"). Each RSU represents a contingent right to receive one share of the Company's common stock. The compensation committee of the Company approved the grant to the reporting person, based on market analysis by Radford of public, pre-commercial and commercial biopharmaceutical companies. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 17:18 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001485003-21-000026 · wf-form4_161411868889400.xml · derivative · entry 1 Sullivan Mark · CIK 0001331843 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-02-19 F1 · derivative.exercise_date: On February 19, 2021, the reporting person was awarded options to purchase 300,000 shares of the common stock of Sesen Bio, Inc. (the "Company"), which options vest 6.25% every three months commencing on January 1, 2021 over four years provided the reporting person is employed by the Company at each such vesting date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 16:57 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantEmployee Stock Option (Right to Buy) · Derivative | 260,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001485003-20-000012 · wf-form4_158206303194870.xml · derivative · entry 1 Sullivan Mark · CIK 0001331843 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: On February 13, 2020, the reporting person was awarded options to purchase 260,000 shares of the common stock of Sesen Bio, Inc. (the "Company"), which options vest 6.25% every three months over four years provided the reporting person is employed by the Company at each such vesting date. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 21:34 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001485003-19-000053 · wf-form4_156505522499089.xml · derivative · entry 1 Sullivan Mark · CIK 0001331843 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-08-01 F1 · derivative.exercise_date: On August 1, 2019, the reporting person was granted an option to purchase 200,000 shares of the common stock of Sesen Bio, Inc. (the "Company"), which option vests 6.25% every three months over four years provided the reporting person is employed by the Company at each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.